Improving vision outcomes in retinal detachment

Improving vision outcomes in retinal detachment

The opportunity

  • Photoreceptor loss following retinal detachment is due to BAX-mediated apoptosis.
  • Selective inhibitors of BAX-mediated apoptosis may represent a promising first-in-class strategy for improving vision outcomes in macula-off retinal detachment.
  • Therapies targeting BAX may also have utility in other back-of-the-eye diseases.

We seek partners for progressing our small molecules that block BAX-mediated apoptosis as first-in-class therapies for retinal detachment.

The technology

Our team has identified multiple small molecule hits from primary phenotypic and targeted screens that inhibit BAX activity.

Scientific figure

Opportunities for partnership

We have:

  • World-class expertise in BAX activation at the structural and cellular level.
  • Established in vitro assays, target ID capability, structure-guided medicinal chemistry and in vivo BAX-driven retinal cell death models.

We are seeking:

  • Partners experienced in medicinal chemistry, regulatory and development path for small molecule development for ophthalmic indications.
  • Investment in our medicinal chemistry program to follow up identified hits; including target ID / mode of action studies and lead optimisation, towards in vivo validation.

Scientific team

Professor Guillaume Lessene, Lead, New Medicines and Advanced Technologies Theme

Professor David Huang, Laboratory head, Blood Cells and Blood Cancer division

Associate Professor Andrew Symons, Vitreoretinal surgeon, Department of Surgery, University of Melbourne

Dr Leigh Coultas, Laboratory head, Epigenetics and Development division

Contact

Dr Anne-Laure Puaux, Head, Commercialisation

Phone: +61 3 9345 2175 

Email: partnering@wehi.edu.au